AbbVie Inc. (FRA:4AB)
167.00
-3.40 (-2.00%)
Last updated: May 13, 2025
AbbVie Revenue
AbbVie had revenue of $13.34B USD in the quarter ending March 31, 2025, with 8.39% growth. This brings the company's revenue in the last twelve months to $57.37B, up 5.45% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$57.37B
Revenue Growth
+5.45%
P/S Ratio
5.69
Revenue / Employee
$1.04M
Employees
55,000
Market Cap
301.93B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 76.54B |
Deutsche Telekom AG | 118.43B |
Allianz SE | 107.35B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.15B |
Rheinmetall AG | 10.48B |
Siemens Energy AG | 37.44B |
Siemens Healthineers AG | 23.14B |
AbbVie News
- 6 hours ago - Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc.(ABBV) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewsWire
- 8 hours ago - Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order. - Barrons
- 13 hours ago - Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV - PRNewsWire
- 1 day ago - Techbio Pioneer Etcembly Signs Deal With DJS Antibodies, Part of AbbVie, to Accelerate Antibody Discovery Pipeline - Business Wire
- 1 day ago - Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know - CNBC
- 1 day ago - Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV - GlobeNewsWire
- 1 day ago - Drugmakers are spared worst-case drug pricing scenario for now - WSJ
- 1 day ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha